Stocks of Chinese pharmaceutical companies posted the worst drop in almost a decade after the drug prices in the government procurement tumbled, sparking concerns that in the future companies will have to make sharp price cut to win government order.
Preliminary results for the tender on Thursday shows that prices on drugs that made into a government procurement list were cut substantially. In particular, the price for one hepatitis B drug was cut by as much as 90 per cent and the price of another made by Jiangsu Hengrui Medicine Co. was reduced by 60 per cent.
The result has . . .
To continue reading, please subscribe.
We highly value independence. Yuan Talks is solely funded by subscriptions from thousands of intelligent readers like you.
What you'll get:
- Systematic, timely and data-driven reporting on China's economy and financial markets with details, data and perspectives you don't read elsewhere!
- Daily Brief newsletter delivered before market open every weekday wrapping up the most important China-related stories.
- Weekly Market Wrap-up on A shares, Chinese bonds, the Yuan and commodities!
- Interviews with China experts. We find you insights you should never miss!
- Conference calls and events. Nothing is better than talking to newsmakers, experts and reporters directly, right?
Already have an account? Sign In